Discover
ASND
Ascendis Pharma A/S
242.95
1 x 242.84
2 x 262.26
bid
ask
-
0.04
0.02%
12:26 PM
timesize
| Ytd | 13.93% | |
| 1y | 20.86% |
240.79
day range
243.77
188.07
52 week range
282.15
| Open | 242.00 | Prev Close | 242.99 | Low | 240.79 | High | 243.77 | Mkt Cap | 15.99B |
| Vol | 222.29K | Avg Vol | 696.32K | EPS | 13.05 | P/E | 18.62 | Forward P/E | 22.51 |
| Beta | 0.38 | Short Ratio | 3.87 | Inst. Own | 103.01% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-30 | 50-d Avg | 242.65 | 200-d Avg | 236.99 | 1yr Est | 308.06 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-11 | 2026-09 | 0.91 | N/A | N/A | N/A |
| 2026-08-13 | 2026-06 | 1.71 | 3.29 | 1.58 | 92.40% |
| 2026-05-07 | 2026-03 | 0.19 | 0.32 | 0.13 | 70.58% |
| 2026-02-11 | 2025-12 | -0.06 | -0.64 | -0.58 | -966.67% |
| 2025-11-12 | 2025-09 | -0.41 | -1.17 | -0.76 | -185.37% |
| 2025-08-07 | 2025-06 | -1.42 | -0.93 | 0.49 | 34.51% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-09-25 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
| 2026-09-15 | Raymond James | Downgrade | Strong Buy | Outperform |
| 2026-09-02 | Oppenheimer | Upgrade | Outperform | Outperform |
| 2026-09-01 | Morgan Stanley | Upgrade | Overweight | Overweight |
| 2026-09-01 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-08-31 | B of A Securities | Upgrade | Buy | Buy |
Profile
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-08-13 | BIENAIME JEAN-JACQUES | Director | 2.90K | Purchase |
| 2026-09-07 | BODENHOFF MADS | Officer | 0.00 | Sale |
| 2026-09-01 | HOLTUG LARS | Director | 4.00K | Sale |
| 2026-05-10 | JENSEN FLEMMING STEEN | Officer | 0.00 | Sale |
| 2026-06-01 | SMITH SCOTT THOMAS | Chief Financial Officer | 4.37K | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Massachusetts Financial Services Co. | 1.88M | 455.68M | 0.00% |
| 2026-06-29 | Blackrock Inc. | 2.21M | 537.45M | 0.00% |
| 2026-06-29 | Westfield Capital Management Co LP | 4.80M | 1.17B | 0.00% |
| 2026-06-29 | Capital International Investors | 1.99M | 483.21M | 0.00% |
| 2026-06-29 | FMR, LLC | 3.55M | 861.54M | 0.00% |
| 2026-06-29 | Artisan Partners Limited Partnership | 2.63M | 640.04M | 0.00% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-05-30 | MFS Series Trust IV-MFS Mid Cap Growth Fund | 1.27M | 309.53M | 0.00% |
| 2026-06-29 | Franklin Custodian Funds-FRANKLIN DYNATECH FUND | 1000.00K | 242.99M | 0.00% |
| 2026-06-29 | JNL Series Trust-JNL/T. Rowe Price Capital Appreciation Fund | 795.73K | 193.35M | 0.00% |
| 2026-06-29 | T. Rowe Price Mid-Cap Growth Fund, Inc. | 639.11K | 155.30M | 0.00% |
| 2026-06-29 | T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App | 3.36M | 817.60M | 0.00% |
| 2026-06-29 | SmallCap World Fund Inc | 570.65K | 138.66M | 0.00% |